American Peptide to expand manufacturing capacity at Vista
Move will enable APC to process large-scale peptide production and meet cGMP standards
The expansion of its facility in Vista, California, US will allow APC to process large-scale peptide production needs while still meeting the high standards of GMP regulations.
The expansion will take place in three main areas of purification, synthesis and lyophilisation.
Four new peptide purification suites will be added for large-scale purification projects. The company also plans to build two new synthesis suites, both for solution phase and solid phase.
For the lyophilisation process, another capacity tray will be added to allow the release of multi-kg single batches of peptide APIs.
‘As the demand for peptide-based therapies increases, we are constantly seeking ways to enhance our operations to meet customer demands for large volumes without compromising our high standards for production,’ said Takahiro Ogata, chief operating officer of APC.
In addition to the expansion of its manufacturing capabilities, APC continues to offer the Total Peptide Management programme as a way of providing customers with increased regulatory support and value-added services. The programme offers a broad portfolio of peptides, and expert consultation to support customers as drug products move from discovery to development and commercialisation.
You may also like
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Ingredients
![CPPs: beating drug delivery barriers]()
CPPs: beating drug delivery barriers
Cell-penetrating peptides are a promising tool for cellular import of drug cargos and have been applied in the delivery of a variety of therapeutic molecules. Jyothi Thundimadathil and Archana Gangakhedkar, American Peptide Co, highlight recent application studies
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Ingredients
![Bicyclic peptides for a new class of targeted drugs]()
Bicyclic peptides for a new class of targeted drugs
Bicyclic peptides are an emerging class of molecules used to explore new cellular sites not treatable using small molecules or large antibodies. Archana Gangakhedkar, American Peptide Company, reveals some of the properties that offer a new route to targeting diseases
Manufacturing
![Beyond the Vacuum Pump: Is your Vacuum System costing more than you think?]()
Beyond the Vacuum Pump: Is your Vacuum System costing more than you think?
Many facilities continue to rely on oil-lubricated vacuum pumps that were installed years ago. The question is no longer whether these pumps work. The question is whether they remain the most efficient solution for today's operational, environmental and productivity requirements
Manufacturing
![Stevanato Group and Aptar Pharma collaborate to accelerate prefilled syringe system selection]()
Stevanato Group and Aptar Pharma collaborate to accelerate prefilled syringe system selection
Joint system-level testing combines Stevanato's glass syringes with Aptar's elastomer components to provide key data earlier in development and inform packaging decisions for sensitive biologics and other injectable therapies
Manufacturing
![Why CAPA keeps failing and what strong organisations do differently]()
Why CAPA keeps failing and what strong organisations do differently
This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk